The detection of virus-specific immunoglobulin M (IgM) antibodies in acute-phase serum samples offers the possibility of making an accurate and rapid serologic diagnosis. We have developed a solid-phase capture assay that uses murine monoclonal antibodies specific for bovine to separate the whole fraction of a bovine serum sample. The specific for bovine herpesvirus-1 (BHV-1) is then detected by the addition of viral antigen, which in turn is detected by BHV-l-specific monoclonal antibodies conjugated to horseradish peroxidase. A BHV-1 antibody response was detected during the early postinfection period (7-40 days PI). Bovine herpesvirus-l antibody was not detected in sera taken from 3 animals following dexamethasoneinduced viral reactivation. This method compares favorably with viral isolation, antigen detection in the clinical samples, and paired serology in the diagnosis of BHV-1 infection at a herd level.
The demonstration of an immune response to viruses is a valid alternative to diagnostic methods based on the isolation of infectious virus or the detection of viral antigens. The advantage of serology is mainly the ease of accessibility of the sample, providing a diagnosis without necropsy specimens. Serologic testing is therefore a method heavily used by practitioners in the diagnosis of bovine herpesvirus-l (BHV-1) and other virus infections of the bovine respiratory tract. Routine serologic diagnosis requires paired serum samples to detect seroconversions or significant rises in titer. This presents the obvious disadvantage of not providing a diagnosis during the acute phase of the disease.
Isotype-specific serology to detect virus-specific immunoglobulin M (IgM) has been used extensively for speeding up the diagnostic serology of viruses. l3 A consistent but transient response is a characteristic feature of infections of viruses that have antigenic uniformity eliciting a long-lasting immunity. Because BHV-1 has been reported 4, 5 to elicit the preceding type of response in a host, the diagnosis of a current infection by BHV-1 can be performed by detection of specific for BHV-1. We report on the development of an antibodycapture enzyme immune assay that was used to detect the BHV-1 response in acute or reactivated infections of cattle.
Materials and methods

Experimental animals and design
Ten healthy 6-month-old calves that were serologically negative for BHV-1 and bovine viral diarrhea virus (BVDV) were infected by simultaneous conjunctival and nasal instillation of 10 6 TCID 50 /animal of BHV-1. a The viral inoculum consisted of a total volume of 2 ml, which was divided in OS-ml aliquots for each conjunctival sac and nostril. Nasal and ocular swabs for viral isolation attempts were obtained immediately prior to the time of inoculation and then daily up to the 20th day postinoculation (PI). Blood samples were collected at regular daily intervals.
At ≥ 90 days PI, 3 of the convalescent animals were treated to reactivate latent BHV-1. The treatment consisted of daily intravenous injections of dexamethasone b (30 mg total) for 5 days, as previously described. l5 Viral reactivation was confirmed by detection of infectious BHV-1 in nasal and ocular secretions after the corticosteroid treatment.
Virus isolation
Viral shedding in nasal and ocular secretions was detected by centrifugal inoculation onto bovine turbinate (BT) cell cultures, following the described procedure. l2
Neutralization assays
Serum neutralizing antibodies were titrated using serial 2-fold dilutions of serum and the immunoglobulin fractions as described. 7 Plaque reduction neutralization assays (PRNA) were performed as described. ll
Serum fractionation and immunoglobulin purification
Extraction and purification of fractions from bovine serum were accomplished by selective precipitation with zinc, followed by gel filtration as described, l,2 with slight modifi-cations. Briefly, serum euglobulins were precipitated from clarified serum by dialysis against a pH 5.4, 0.01 M potassium phosphate buffer for 24 hr at 4 C. The precipitates were washed twice with the dialysis buffer and redissolved in a pH 5.4, 0.01 M acetate buffer containing 0.15 M NaCl. The redissolved fractions (20% of the initial serum volumes) were treated with a 0.1 MZnSO 4 solution by adding dropwise with constant stirring to achieve a final concentration of 25 mM. The preparations were stirred at 25 C for 2 hr prior to centrifugation at 8,000 x g for 15 min. Excessive zinc ions were chelated by the addition of tetrasodium EDTA to 1% (w/v). After removal of the ZnSO 4 precipitate, supernatants were applied to a 2.5 x l00-cm ascending-flow column of Sephacryl S-400 c equilibrated with a pH 8.6, 0.1 M Tris-HCl buffer containing 1 M NaCl and 0.02% sodium azide. The absorbance peaks were pooled and concentrated to small volume by ultrafiltration. The immunoglobulin fractions were then dialyzed for 3 days against 3 changes of phosphatebuffered saline (PBS), pH 7.6, at 4 C, and stored at -70 C until used.
Extraction and purification of IgG fractions were performed by 2 cycles of precipitation with 33% NH 4 S0 4 , followed by centrifugation at 8,000 x g for 20 min, rinsing, and extensive dialysis against PBS. The dialysate was submitted to gel filtration through a 2.5 x l00-cm ascendingflow column of Sephadex G-200 c (J. E. Butler, University of Iowa, Iowa City, IA, personal communication, 1987). The corresponding absorbance peaks were pooled and concentrated to small volume by ultrafiltration. The immunoglobulin fractions were dialyzed and stored as described above. The isotype identity and purity of peak of the fractions were confirmed by radioimmunoassay as described below.
Bovine isotype-specific monoclonal antibodies
Murine hybridomas secreting monoclonal antibodies (MAB's) against bovine IgG, (DAS-17), IgG 2 (DAS-2), IgM (DAS-6 and DAS-11), IgA (DAS-7), and the light chain (DAS-9) have been described. 16, 17 Each of the MAB's was purified from ascites fluids by affinity chromatography on columns of cyanogen bromide-activated Sepharose 4B conjugated to its respective antigen. Affinity-purified MAB DAS-9 was labeled with 125 I according to previously described procedures. l 7
Sandwich radioimmunoassay
Polyvinyl chloride 96-well microtiter plates were coated with the affinity-purified isotype-specific MAB's (30-l00 µg/ ml PBS; 20 µl/well) and incubated overnight at room temperature in a humid chamber. After incubation, blocking of unbound sites was performed by incubation for 1 hr with 0.1% ovalbumin in PBS. Washing with 0.05% Tween 20 PBS followed. To optimize the IgM capture assays, varying concentrations of monoclonal bovine IgG l , IgG 2 , IgM, and IgA (62.5-800 ng/ml in growth media) were then placed in the wells (20 µg/well). 16 After a 1-hr incubation at room temperature, the wells were washed 3 x with PBS-Tween (0.01 M PBS and 0.05% Tween 20), and 125 I-labeled MAB DAS-9 (light-chain-specific; 20,000 counts/min in 20 µl/well) was added. After another 1-hr incubation, the wells were washed 3 x with PBS-Tween, cut, and counted for bound radioac-tivity. Standard curves were established for counts per minute (CPM) against nanograms of bovine immunoglobulin per milliliter added.
For the determination of purity and specificity of serum fractions, varying concentrations of the immunoglobulin fractions were placed on plates coated with the corresponding isotype-specific MAB (DAS-11, DAS-2, or DAS-17) and the sandwich radioimmunoassay was performed as described above.
IgM antibody-capture enzyme immune assay
A) Reagents. MAB DAS-11 or DAS-6 was used as capture antibody adsorbed to the plastic solid phase. Viral antigen was prepared by infecting BT cell monolayers grown on 850-cm 2 roller bottles with BHV-l a at a multiplicity of infection ranging from 1 to 3. The infection was allowed to continue until advanced cytopathic effect (80-l 00%; 36-48 hr) was evident. The BHV-1 was harvested by removal of the cell monolayer by scraping, then pooling fluids, and 3 subsequent cycles of freeze/thaw. The cell culture medium was clarified by centrifugation (1,500 x g at 4 C) and concentrated by hollow-filter ultrafiltration. d The concentrated virus was layered onto a 3-ml cushion of 40% sucrose and centrifuged at 80,000 x g for 1 hr at 4 C. The supernatant was discarded and the viral pellet resuspended in tris-EDTA buffer at 1 / 20 of the original volume and stored at -70 C.
The murine MAB's 113, 155, and 105 (S. Srikumaran, unpublished results, 1987) , which are directed against BHV-1, were conjugated with horseradish peroxidase (HRPO) according to a described protoco1. 21 B) The IgM antibody-capture enzyme immune assay. The affinity-purified MAB DAS-11 was diluted to 25 µg/ml in carbonate buffer (pH 9.6). One hundred microliters of DAS-11 solution were added per well to 96-well polystyrene plates" and incubated overnight at 4 C. After aspiration of the capture MAB DAS-11, blocking of the solid phase was accomplished with turkey serum diluted 1:20 in carbonate buffer (pH 9.6). Incubation at 37 C for 30 min followed. After washing 2 x with PBS-Tween, the plate was patted dry on a paper towel. For determination of BHV-l-specific IgM antibody end-point titers, 2-fold dilutions (starting at 1:20) of test samples in PBS-Tween were added to wells B-H of each vertical row (volume: 50 µl/well). Well A was filled with a 1:20 dilution of the test sample. After incubation for 1 hr at 37 C, plates were washed as before and a solution of BHV-1 antigen (400-600 µg/ml) was added to wells B-H (volume: 50 µl/well). A control (uninfected cell monolayer) antigen was added to row A. Plates were incubated for 1 hr at 37 C and washed as before. A pool of HRPO-conjugated MAB's anti-BHV-1 was added to each well (volume: 50 µl/ well) and incubated at 37 C for 1 hr. Diluent consisted of PBS-Tween with 4% turkey serum. After washing as described, peroxidase substrate ABTS f was added and incubated at room temperature for 20 min. At that time the reaction was stopped with ABTS peroxidase stop solution. f The absorbance was read at 410 nm on a dual-wavelength ELISA reader. g The results of the enzyme immune assay were expressed as S/N ratios, which were calculated as the mean OD 410 from duplicate wells incubated with the sample (S) divided by the mean OD 410 of duplicate wells incubated with the "BHV-1 IgM-negative" serum (N) (see below). Only samples giving an S/N ratio ≥2 were considered positive for BHV-1-specific IgM antibodies.
In all cases, optimal dilutions of the capture MAB, antigen, and conjugate were determined by "block" titrations. For a single-serum diagnostic screening test, sera were tested at a single dilution of 1:20 on duplicate wells of both "viralantigen" and "uninfected cell control" rows.
Reference control sera consisted of a "BHV-1 IgM-positive" serum, which was an early postinoculation sample (12 days PI), and a "BHV-1 IgM-negative" serum, which was obtained from a latently infected BHV-1 hyperimmune animal. The BHV-1 IgM status of these reference control sera was confirmed by serum neutralization (SN) and PRNA as well as by isotype-specific enzyme immune assays. These tests were performed on the immunoglobulin fractions of the reference sera.
Results
Sensitivity and specificity of the capture MAB
The sensitivity of the MAB DAS-11 for the detection of varying amounts of bovine IgM using a solid-phase radioimmunoassay is shown in Fig. 1 . At the coating concentration used in the antibody-capture enzyme immune assay (25 µg of MAB/ml), DAS-l1 recognizes only bovine IgM, with no cross-reactivity with the other immunoglobulin classes and isotypes.
Isotype specificity of the ELISA test
The titration curves for BHV-1 IgM activity obtained by end-point titration of 2 reference sera using the enzyme immunoassay capture format are shown in Fig. 2 . The shape of the titration curve is consistent with the characteristics of a solid-phase capture assay. It is apparent that up to a dilution of 640 there was a constant level of antigen-conjugate binding, indicative of a saturation of the solid phase with BHV-1 IgM (Fig.  2) . The end-point ELISA titers for the immunoglobulin G (IgG) and IgM purified fractions of the "BHV-1 IgMnegative" serum are given in Fig. 3 . Likewise, the BHV-1 antibody activities present in the purified IgG and IgM fractions of both reference sera are shown in Table 1 . The IgG fraction of the "BHV-1 IgM-negative" serum contains significant anti-BHV-1 activity, as measured by both isotype-specific enzyme immunoassay and SN. However, no IgM specific for BHV-1 was detectable in the "BHV-1 -negative" serum. ulated (Fig. 4) . A specific IgM antibody response was measurable starting at day 7 PI, reaching a peak of maximum activity around day 12 PI. The BHV-1 IgM activity remained detectable (although steadily declining) in all 4 animals for at least 3 weeks, eventually disappearing at 30-40 days PI (Fig. 4) .
The relationship between the earliest positive BHV-1 IgM response and the appearance of clinical and virological signs of infection was studied in 10 animals ( Fig. 5 ).
Study of the IgM response during induced reactivation of BHV-1
Three latently infected animals were treated with corticosteroids in an attempt to reactivate BHV-1. Recrudescence of virus and a rise in SN antibody titer occurred in two animals ( Table 2 ). Calf A excreted BHV-1 on days 3-8, and calf B shed virus only on days 12 and 13 posttreatment. In both cases significant rises in the BHV-1 antibody titer occurred between 5 and 7 days after viral excretion, but IgM activity was negative. The screening for BHV-1 IgM during reactivation was performed at 3 different dilutions (l/20, l/500, l/1,000) of each serum, with negative results. 
Discussion
The enzyme immune assay described in this study permits the specific detection of BHV-1 IgM in whole serum.
The BHV-l-specific IgM antibody response appeared first at 7 days PI and persisted for a period of approximately 40 days PI. This finding is in agreement with previous reports on the kinetics of isotypic response during BHV-1 infection. 4, 5, 14 The early and transient character of the BHV-1-specific IgM response can be used as an assessment of the recency of infection of the animals. The earliest positive IgM reaction in the experimental group was at day 7 PI, with all animals positive for BHV-1 IgM on day 10. This corresponds to a period of 3-6 days after appearance of clinical disease. It suggests that some of the first animals to exhibit clinical signs of infection in the herd may exhibit positive BHV-1 IgM reactivity when an "acute-phase" serum sample is drawn.
The ability of herpesviruses to establish latent infections that can be reactivated has always been a matter of concern when assessing the diagnostic value of IgM serology for this group of viruses. l3 It has been postulated that the positive herpesvirus IgM reactivity should only be considered as an indication of a recent "active" infection that could be of an acute or reactivated nature. l3 In our experiments, no BHV-1 IgM response was detected following dexamethasone-induced reactivation of latent BHV-1 in 2 animals. In addition, although reactivation of BHV-1 did not occur in the third dexamethasone-treated animal, a significant rise in SN antibodies was demonstrated at a later time (during periodic follow-up bleedings), suggesting a spontaneous recrudescence. No BHV-1 IgM activity could be detected in association with this recrudescence. End-point ELISA IgG titers obtained on the sera collected during reactivation (using capture assays with MAB's DAS-2 and DAS-17) suggest that the seroconversions detected during BHV-1 reactivation were primarily caused by a rise in circulating BHV-l-specific IgG isotypes. This observation is in contrast with data reported by others. 4, 6 It could be argued that the observed difference may be due in part to differences in experimental protocols (i.e., differences in levels of replication of initial inocula and/or subsequent antigenic re-exposure upon reactivation, differences in sensitivity of the assays, cross-contamination of immunoglobulin fractions, etc.). However, the presence or absence of an IgM response during a herpesvirus reactivation is not a consistent feature. In reactivations of herpes simplex virus an IgM antibody response is rarely seen and then associated with cases of severe secondary encephalitis. 9, 19 On the other hand, the presence of IgM antibody response during herpes zoster reactivation is a very frequent observation. l8 During reactivation of human cytomegalovirus, both low (7%)" and high (78%) 10 incidences of IgM responses have been reported. Additionally, in pseudorabies viral infections, an IgM response may or may not be present during reactivation (M. Snyder, Agritech, Inc., Portland, ME, personal communication, 1987).
The potential inability of the BHV-1 IgM enzyme immune assay to differentiate between a primary or a recurrent infection would not diminish the validity of the assay when compared with the other tests that are currently used to diagnose BHV-1 infections, such as viral isolation, antigen detection, or paired serology. These tests also fail to differentiate between the two.
The format of an antibody-capture enzyme immune assay makes it particularly suitable to assay active infection with viruses like BHV-1, which are enzootic within the bovine species and produce a high prevalence of immunity (i.e., BHV-1 IgG). The principle of capturing and separating the bovine IgM minimizes the chance of any possible interference in the detection of IgM due to competition of BHV-1 IgG or to interference from any other serum components (i.e., a putative rheumatoid factor of cattle). In addition, the use of the MAB DAS-11 as a capture antibody for bovine IgM circumvents problems of specificity, consistency, and supply that may hinder the standardization of an enzyme immune assay. This enzyme immune assay format may provide the basis for the screening of virusspecific IgM of other agents involved in bovine respiratory disease. The value of this type of test has been reported recently for bovine respiratory syncytial virus. 20 It will be interesting to assess the usefulness of this BHV-1 IgM enzyme immuneassay for diagnosis of BHV-1-induced abortion, for which the conventional paired serology is particularly unrewarding. 8 
